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included a reduction in blood pressure and transient tachy-Recombinant human insulin-like growth factor-1 induces an
cardia.anabolic response in malnourished CAPD patients.
Conclusion. Injections of rhIGF-1 induce a strong and sus-Background. Insulin-like growth factor-1 (IGF-1) is an ana-
tained anabolic effect, as indicated by a positive nitrogen bal-bolic hormone that mediates most of the growth effects of
ance in CAPD patients with protein-energy malnutrition.growth hormone. This study tested the hypothesis that recom-
rhIGF-1 administration may be an effective method for treatingbinant human IGF-1 (rhIGF-1) will induce an anabolic re-
malnutrition in maintenance dialysis patients.sponse in malnourished patients undergoing continuous ambu-
latory peritoneal dialysis (CAPD).
Methods. Six CAPD patients with protein-energy malnutri-
tion underwent nitrogen balance studies in a clinical research Many adult patients undergoing either maintenancecenter for 35 days each. Throughout the study, patients were
hemodialysis or chronic peritoneal dialysis show evi-maintained on their same CAPD regimen prior to hospitaliza-
dence for protein-energy malnutrition [1–3]. The inci-tion, and were fed a constant protein and energy intake that
was similar to their diet prior to hospitalization. The first 15 dence of malnutrition in chronic peritoneal dialysis pa-
hospital days were a baseline period; during the subsequent tients is reported to range from approximately 18 to
20-day period, patients were given subcutaneous injections of 56% [4, 5]. Many factors may engender malnutrition inrhIGF-1 (100 mg/kg/12 h), except for one patient who received
maintenance peritoneal dialysis patients [6]. Inadequate50 mg/kg/12 h for the first five days, followed by 100 mg/kg/12
intake of protein and energy is considered to be an im-h for the following 15 days.
Results. During the treatment with rhIGF-1, serum IGF-1 portant factor. Evidence also suggests that resistance to
increased by about 100% (P 5 0.03), and nitrogen balance the anabolic effects of growth factors may contribute to
became strongly positive (12.0 g/day, P 5 0.015 vs. baseline). the propensity for protein-energy malnutrition in main-This anabolic effect was observed within hours after commenc-
tenance dialysis patients. Because malnutrition is an im-ing the rhIGF-1 treatment and was largely caused by a 20%
portant risk factor for morbidity and mortality in bothdecrease in peritoneal dialysate effluent nitrogen. There was
a proportionate reduction in urine nitrogen and serum urea maintenance hemodialysis and chronic peritoneal dial-
nitrogen. This decrease in nitrogen output was sustained during ysis patients [7], this issue appears to be of considerable
the entire 20 day of treatment with rhIGF-1. Serum phosphorus clinical importance.
decreased significantly during the first several days of rhIGF-1
With the availability of growth factors manufacturedtreatment, whereas serum calcium increased significantly dur-
by recombinant DNA techniques, a number of studiesing the rhIGF-1 treatment. Serum potassium and albumin did
not change during the rhIGF-1 injections. There was no change have examined the nutritional effects of these com-
in body weight and body composition, as assessed by anthro- pounds in malnourished patients. In the past years, the
pometry during the baseline or treatment phases of the study. most commonly used anabolic agent evaluated has been
Some patients exhibited minor possible adverse events that recombinant growth hormone (rhGH). This hormone
induces an anabolic response that has been observed in
both acutely catabolic patients without renal disease and1 The current address of Dr. Fouque is Department of Nephrology,
Hoˆpital Edouard Herriot and University Claude Bernard, Lyon, chronically malnourished patients in advanced renal fail-
France. ure [8–10]. However, the effectiveness of rhGH may be
markedly attenuated in both severely septic individualsKey words: insulin-like growth factor, nutrition, peritoneal dialysis,
anabolism, protein-energy malnutrition. and in malnourished subject with a low protein and/or
energy intake [11].
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Table 1. Characteristics of the subjects at onset of studytory type illnesses [12]. We therefore evaluated whether
insulin-like growth factor-1 (IGF-1), the hormone re- Number M/F 4/2
Age years 43.764.8sponsible for at least most of the anabolic effects of
Duration of CAPD months 7.561.5growth hormone, would be effective in promoting an Hematocrita % 32.763.5
anabolic response. Patients undergoing continuous am- Hemoglobina g/dL 10.961.1
Serum urea nitrogena mg/dL 67.0615.2bulatory peritoneal dialysis (CAPD) who had protein-
Serum creatininea mg/dL 11.361.2energy malnutrition were studied. Each patient had Body weighta kg 68.4610.8
documented marginal or low protein intakes that were Heighta cm 15966
Relative body weighta % 100611considered to be a cause of their malnutrition. Each
Mid-arm muscle circumferencea cm Male: 26.562.7patient was studied in the hospital for 35 days and re- Female: 23.662.0
ceived a constant protein and energy diet in order to Biceps skinfolda mm Male: 8.263.2
Female: 7.164.0exclude the possibility that a change in dietary intake
Triceps skinfolda mm Male: 14.466.3might influence the metabolic response during the study. Female: 16.262.1
After a 15-day baseline phase, patients entered a treat- Subscapular skinfolda mm Male: 12.262.8
Female: 11.662.4ment phase, in which they received recombinant human
Body fata % Male: 24.564.2IGF-1 (rhIGF-1), 50 to 100 mg/kg body wt every 12 hours Female: 27.165.2
for the next 20 days. The results indicate that treatment Body mass indexa kg/m2 Male: 25.563.8
Female: 25.964.3with rhIGF-1 strongly increased nitrogen balance and
Dietary energy intakeb kcal/kg/day 2662was well tolerated. Dietary protein intakeb g/kg/day 1.0360.09
Values are expressed as mean 6 sem, N 5 6.
a Data were obtained at onset of the Baseline PhaseMETHODS b Data obtained from three day home dietary records followed by dietitian
interviews prior to entering the study; energy intake from dialysate d-glucosePatients was not included in these estimates
This study was performed in the Clinical Research
Center at Harbor-UCLA Medical Center and was ap-
proved by the Institutional Human Subjects Committee.
betes mellitus, any illness requiring hospitalization orAll patients gave signed informed consent. One patient
one episode of peritonitis within the previous 30 days,was discontinued from the study on the third day of the
more than one episode of peritonitis in the past sixbaseline phase after she developed an episode of acute
months, the presence of cancer except basal cell carci-pancreatitis with nausea. Another patient was discharged
noma, severe liver, lung, or heart failure, vasculitis, psy-from the study during the baseline phase because of the
chosis, or if they were not clinically stable.inability to comply with the diet. Data from the re-
maining six patients who completed the study are re-
Study designported (Table 1).
Patients were studied in the Clinical Research CenterThe eligibility criteria for participation in the study
at Harbor-UCLA Medical Center for 35 days. Through-included (a) a diagnosis of protein and/or energy malnu-
out the 35 day study, patients were fed a constant diettrition, (b) treatment with CAPD for at least four
that was calculated to provide a daily dietary proteinmonths, and (c) ages 18 to 75 years. Protein and/or en-
and energy intake similar to their diet prior to enteringergy malnutrition were diagnosed by the presence of at
the study. For each patient, the daily intake of bothleast two of the following: (a) evidence for muscle wast-
energy and protein was divided into portions of approxi-ing by clinical appraisal or by decreased midarm muscle
mately 2/8, 2/8, 3/8, and 1/8 for consumption at breakfast,circumference, (b) body weight of 90% or less of the
lunch, supper, and evening snack, respectively. Dietarydesirable body weight or a serum albumin of 3.7 g/dL
fat, sodium, and potassium intakes were designed to beor lower, and (c) an inadequate dietary protein and/or
similar to the patient’s prestudy intake. The diets wereenergy intake prior to entering the study (that is, a pro-
prepared using metabolic kitchen protocols that havetein intake of 1.0 g/kg actual body wt per day or less
been employed in previous studies [13]. Any requests toand/or an energy intake of 30 kcal/kg actual body wt per
change food intake were strongly discouraged after theday or lower). Dietary protein intake was determined
first three to four days of the study. All patients werefrom a three-day dietary diary kept by the patient and
given one tablet per day of a multivitamin containinga dietary interview with the research dietitian during the
folate (Nephrovitee; R&D Laboratories, Santa Monica,screening period before the patient was accepted into
CA, USA) and an iron supplement. Patients often re-the study.
ceived other medicines typically prescribed for chronicPatients were excluded from the study if their renal
dialysis patients, including antihypertensive medications,creatinine clearance was greater than 5.0 mL/min or if
they had insulin-dependent or insulin-independent dia- erythropoietin, phosphate binders, and various other
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agents. No patient was started or stopped on erythropoi- Blood for the measurement of serum urea, creatinine,
potassium, phosphorus and calcium, albumin, and IGF-1etin therapy during the study or within several weeks
before commencing the study. was obtained in the postabsorptive state after an over-
night fast, before any injection or medicinal intakes, be-Four patients received CAPD with four dialysate ex-
changes per day that provided 2.0 L per exchange; one tween 7:45 and 8:00 a.m. at the beginning of days 1, 6,
11, 16, 21, 26, and 31, and at the end of day 35 (that is,small young woman received 1.5 L per exchange, five
times per day, and a large man underwent four 2.5 L the beginning of day 36). Serum total protein and plasma
amino acids were measured at the beginning of days 1,exchanges per day. The glucose concentrations of the
individual dialysate exchanges were 1.5, 2.5, and 4.25%, 16, and 36. Blood for the plasma amino acid analyses
was drawn after an overnight fast before breakfast be-depending on the ultrafiltration needs of the patient.
Once the study began, an effort was made to not change tween 7:45 and 8:00 a.m.
the glucose concentration of the dialysate in order to
Anthropometryprevent alterations in the glucose and energy intake de-
livered to the patient. If a change in the glucose concen- Anthropometry was collected at the beginning of days
1, 16, and 36 for each patient as previously describedtration of a dialysate bag was made, a corresponding
adjustment in the dietary intake was made, based on the [15]. The relative body weight (RBW) is the patient’s
weight 3 100 divided by the median weight of normalestimated fraction of glucose absorbed from the dialysate
[14], to prevent changes in the total (diet plus dialysate) individuals of the same height, gender, frame size, and
age range as the patients and determined from theenergy intake.
The first 15 days of the study were considered a base- HANES II data [16]. Skinfold thickness measurements
were performed in triplicate at four different locations,line phase during which each patient underwent a CAPD
regimen similar to his/her prestudy treatment. For the that is, biccipital, tricipital, subscapular, and suprailiac.
Fat mass was determined from Durnin and Wormersleyfour daily exchanges, the instillation of fresh dialysate
was generally started at 8:05 a.m. (after the morning tables [17].
blood drawing and rhIGF-1 injection), 1:00 p.m., 5:00
Preparation of rhIGF-1 for injectionp.m., and 11:00 p.m. The drainage of dialysate was initi-
ated about 15 minutes before instillation of the next Recombinant IGF-1 was obtained in vials containing
9.8 mg of pure dry rhIGF-1 and 0.3 mg of sulfoxideexchange, except for the morning drainage, which was
begun at 7:30 a.m. to allow time for weighing the patient (generously given by Ciba-Geigy Corp., courtesy of Dr.
H.P. Guler), and stored at 48C. For preparation of theand for blood drawing before the 8:05 a.m. instillation.
During the treatment phase, from days 16 through rhIGF-1 for administration, normal saline (0.98 mL) was
slowly injected into the vial. The vial was then gently35, patients continued to undergo the same dietary and
dialysis regimen, except that each day the patients re- rotated along its long axis for about 15 seconds to avoid
bubble formation. The rhIGF-1 solution was then rapidlyceived two subcutaneous injections of rhIGF-1 in the
abdominal wall at 8:00 a.m., after blood drawing, and transferred into an insulin syringe to be injected subcuta-
neously. The maximum time between dilution and injec-8:00 p.m. The first patient studied received 50 mg/kg of
rhIGF-1 every 12 hours. At five days, this patient exhib- tion of rhIGF-1 did not exceed 20 minutes.
ited almost no decrease in his serum and dialysate urea.
Methods of measurementsThe dose of rhIGF-1 was then increased on day 6 to 100
mg/kg every 12 hours and was maintained at this level Blood for amino acid analyses was collected in tubes
containing dry heparin, centrifuged immediately at 2300for all subsequent patients throughout their treatment
phase. g for 15 minutes at 48C, and prepared as previously
described [18]. One milliliter of the supernatant wasNitrogen balances were measured continuously in
each patient for the entire 35 days of the metabolic study added to 45 mg of crystalline sulfosalicylic acid and was
centrifuged. The deproteinized supernatant was frozenusing previously described techniques [13]. Total nitro-
gen was measured in pools of the patient’s daily food at 2708C until analyzed. The amino acid analyses were
usually performed within one month of obtaining theintake, prepared in duplicate for analysis at least five
times during the study in each patient, in each 24-hour plasma.
Serum urea, creatinine, potassium, phosphorus, cal-pool of dialysate outflow, in urine collected daily or for
oliguric patients with less than 500 mL urine output per cium, and albumin were measured in the hospital clinical
laboratory at Harbor-UCLA Medical Center. Albuminday, in five day urine pools, and in feces collected during
the same five-day pools. Nitrogen balances were calcu- was assayed by the bromocresol green method, and
plasma amino acids were determined with a Beckmanlated for each of the five-day collection periods and were
adjusted for changes in body urea nitrogen, as previously Model 6300 in the research laboratory at Harbor-UCLA.
Total nitrogen was measured by pyrochemiluminescencedescribed [14].
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Table 2. Serum chemistries and weights in malnourished CAPD patients before (days 1 to 15) and during (days 16 to 36)
twice daily rhIGF-1 injections
Baseline period rhIGF-1 injections
Days 1a 6 11 16b 21 26 31 36
Serum urea 67.8 60.8 57.4 54.0c 45.7 40.3 40.4 40.5e
nitrogen mg/dL 68.9 67.0 66.5 66.5 66.3 64.9 63.9 64.5
Serum albumin 3.10 3.18 3.02 2.83 2.80 2.88 2.92 3.03
g/dL 60.12 60.17 60.18 60.15 60.16 60.16 60.15 60.15
Serum potassium 4.05 3.97 3.97 4.17 4.02 4.00 4.27 4.27
mEq/L 60.26 60.19 60.23 60.33 60.28 60.23 60.34 60.22
Serum phosphorus 5.17 4.97 4.52 4.37 3.67 3.50 3.37 3.62d
mg/dL 60.38 60.34 60.37 60.29 60.23 60.22 60.29 60.21
Serum calcium 8.58 8.43 8.63 8.51 8.83 8.92 9.17 9.08d
mg/dL 60.25 60.27 60.28 60.24 60.12 60.17 60.20 60.16
Body weight 66.7 66.1 65.6 65.8 66.5 66.9 66.6 66.6
kg 67.3 67.7 67.5 67.4 67.7 67.7 67.7 67.8
Values are expressed as mean 6 SEM, N 5 6.
a Data obtained before the study protocol were commenced on the first day of the study
b The blood and weight measured on day 16 were obtained before the patient received the initial dose of rhIGF-1
c Significant decrease during the Baseline phase (P , 0.05, ANOVA).
d Significant change during the Treatment phase (P , 0.025, ANOVA).
e Significant decrease during the Treatment phase (P , 0.0005, ANOVA).
with an Antek Nitrogen Analyzer Model 401 (Antek 3.10 6 0.12 g/dL. No patient had a history of diabetes
Instruments, Inc., Houston, TX, USA). mellitus.
Serum total IGF-1 was measured in duplicate by radio- During the entire 35 day study, the grand means for
immunoassay using a polyclonal rabbit antibody after the dietary protein intake, determined by nitrogen analy-
acid ethanol extraction, followed by cryoprecipitation, ses of duplicate diets, and dietary energy intake were
as previously described [19]. 1.03 6 0.09 g/kg/day and 26 6 2 kcal/kg/day, respectively.
In the baseline phase, the serum urea decreased signifi-
Statistical analyses cantly (P 5 0.03; Table 2 and Fig. 1), which may indicate
Data were analyzed by analysis of variance and paired that in the hospital, the patients were more compliant
t-tests. The nitrogen balance data were analyzed by a to their dialysis regimen or that despite our efforts to
repeated-measures multivariable analysis of variance. maintain the dietary protein intake in the hospital at
For statistical comparisons of the baseline and treatment prestudy levels, the patients’ dietary protein during the
phases, the first five days of baseline (days 1 to 6) and study was lower than their prehospital intake. The mag-
of the treatment (days 16 to 20) were excluded from the nitude of the fall in the serum urea nitrogen (SUN) was
analysis in order to allow for equilibration if it were to greater during the first five days of baseline (1.41 mg/
occur. If a significant time versus treatment interaction dL/day) and was then averaged 0.68 mg/dL/day for the
was observed, paired t-tests were performed comparing next 10 days (Table 2). After commencing rhIGF-1 treat-
days 6 through 10 to days 21 through 25, days 11 through ment, the rate of fall in SUN increased to 1.66 mg/dL/
15 to days 26 through 30, and also the averages of the day for the first five days of treatment (Table 2). Subse-
two control periods to the three treatment periods. Data quently, the rate of fall in SUN decreased so that a
are expressed as mean 6 SEM. plateau in SUN levels was observed by about the 10th
day of the treatment phase (Table 2 and Fig. 1).
A similar pattern was observed for serum phosphorusRESULTS
concentrations (Table 2). The greatest decrease in serumCharacteristics of the six patients at the onset of the
phosphorus was observed during the first five days ofstudy are shown in Tables 1 and 2. Five individuals were
the treatment phase. Serum calcium was not modifiedHispanic, and one was of European descent. The mean
during the baseline phase. However, there was a signifi-dietary protein and energy intakes of the six patients,
cant increase in serum calcium after commencingdetermined from three-day dietary diaries and interviews
rhIGF-1 that was sustained during the 20-day treatmentconducted during the days before entering the hospital,
period (P 5 0.01 vs. baseline; Table 2). No change waswere below the recommended values [20]. The average
observed for serum potassium levels, possibly becauseRBW (100 6 11%) was normal; however, two patients
several patients were given a potassium supplement towere below 90% of standard body weight, as determined
prevent hypokalemia or for serum albumin.from the NHANES data, which is an indication of
protein-energy malnutrition. Serum albumin averaged Body weight (Table 2) and other anthropometric mea-
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Fig. 1. Daily nitrogen balance (histograms)
values on the left vertical axis, obtained in
three of the six patients. The close circles
(right vertical axis) represent the serum urea
nitrogen (SUN) profile as measured every five
days in all patients (statistic shown in the text,
Table 2, and Table 5). Recombinant insulin-
like growth factor-1 (rhIGF-1) treatment was
commenced on day 16. After that, blood was
drawn for serum urea nitrogen (SUN) deter-
mination. Day 16 nitrogen balance was calcu-
lated after that each patient received the two
first rhIGF-1 injections.
Table 3. Changes in serum albumin and anthropometric parameters
End of baseline End of rhIGF-I treatment
(Day 16) (Day 36)
Serum total protein g/dL 5.660.21 5.6860.25
Mid-arm circumference cm 31.1062.26 31.2663.41
Mid-arm muscle circumference cm 26.3861.42 26.9462.35
Biceps skinfold mm 8.5061.74 8.4663.16
Triceps skinfold mm 14.8363.05 13.3664.20
Sub-scapular skinfold mm 13.1161.49 15.6262.71
Body fat % 25.9062.46 26.2663.72
Serum total protein concentrations were obtained from all six patients; anthropometric data were obtained from five subjects.
Table 4. Plasma amino acids in malnourished CAPD patients before The nitrogen balance data are shown in Table 5 and
(days 1 and 16) and after (day 36) intake of rhIGF-1
Figure 1. The grand mean of the dietary nitrogen intake
Day in the six patients averaged 8.70 g/day, which is equiva-
1a 16 36 lent to 54.4 g protein/day or 0.82 g protein/kg/day. Some
patients lost a small amount of dietary nitrogen as emesisTotal amino acids, lmol/L 3119 2805 2820
683 6148 6170 or uneaten food on one or two occasions, and their daily
Total essential amino acids, lmol/L 849 727 645 nitrogen intake was slightly lower on those days. The
620 650 664
major route of nitrogen output was dialysate, which de-Total nonessential amino acids, lmol/L 2139 1968 2078
677 6105 6108 creased by approximately 20% within the first five days
Values are expressed as mean 6 sem, N 5 6. Blood was obtained for plasma of instituting rhIGF-1 treatment (Table 5). Urine nitro-
amino acid measurements before breakfast, and between 7:45 a.m. and 8:00 a.m., gen also decreased by about 35% within the first five daysafter an overnight fast.
a Data obtained before the study protocol was commenced on the first day of of rhIGF-1 treatment (Table 5). In the three patients in
the study whom nitrogen balance was measured daily, dialysate
nitrogen output and urine nitrogen excretion decreased,
and nitrogen balance became positive within 24 hours
of the inauguration of rhIGF-1 injections (Fig. 1). Theresures (Table 3) did not change significantly during the
was no change in fecal nitrogen output during the study.course of treatment with rhIGF-1. There was no change
Nitrogen balance, adjusted for changes in body ureain postabsorptive plasma total essential amino acids, to-
nitrogen, was similar during the last two five-day balancetal nonessential amino acids, or total amino acids be-
periods of the baseline phase (Table 5). Nitrogen balancetween the end of baseline (day 16) and the day of onset of
was positive by 0.52 6 0.44 g/day and was not differentthe study (day 1; Table 4). During the rhIGF-1 treatment
from zero during these two periods. These findings indi-phase, there was also no significant change in plasma
total essential, total nonessential, or total amino acids. cate that the patients had attained a steady state for
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Table 5. Nitrogen balance in malnourished CAPD patients during baseline (days 1 to 15) and during intake of rhIGF-1 (days 16 to 36)
Duration Dietary N Adjusted N
of period intake balance
Period days g N/day g N/day
D Body Total
Dialysate Urine Feces urea N Output
g N/day
Baseline phase
1 1–5 8.7060.43 6.7260.70 0.9560.45 1.4160.06 20.6360.40 9.1260.66 10.226 .43
2 6–10 8.7060.43 6.2160.47 0.7760.35 1.4060.08 20.1960.15 8.4260.39 10.476 .41bc
3 11–15 8.7060.43 6.1560.41 0.7360.35 1.4260.06 20.1560.08 8.3360.41 10.576 .48bd
Mean 6SEM 8.7060.43 6.3660.31 0.8160.21 1.4160.04 20.3260.15 8.6260.29 10.426 .25
Treatment phase
4 16–20 8.7060.43 5.3960.49 0.5960.29 1.3560.06 20.7060.21 7.3660.39 12.046 .47
5 21–25 8.7060.43 5.2260.50 0.5660.29 1.3760.05 20.3860.12 7.1860.42 11.916 .30bc
6 26–30 8.7060.43 4.8960.34 0.5360.28 1.3560.05 10.00260.13 6.8560.31 11.926 .14bd
7 31–36 8.7060.43 4.7760.41 0.4560.28 1.3260.03 20.0160.14 6.5460.42 12.016 .25b
Mean 6SEM 8.7060.43 5.0760.09 0.5360.13 1.3560.02 20.2760.09 6.9860.19 11.976 .15a
Values are expressed as mean 6 SEM, N 5 6.
a An overall increase from Baseline, P , 0.0001 (ANOVA)
Differences between periods (t-test): b 5 1 6 1 7 vs. 2 1 3, P 5 0.015; c 5 vs. 2, P 5 0.004; d 6 vs. 3, P 5 0.04
neutral protein balance at the end of baseline. After
rhIGF-1 treatment was initiated, nitrogen balance be-
came strongly positive by about 2.0 g per day and re-
mained positive at this magnitude for the duration of
the study (Table 5). The difference between nitrogen
balance, after equilibration, during the last 10 days of
baseline and the last 15 days of treatment with rhIGF-1,
was statistically significant (0.52 6 0.44 vs. 1.95 6 0.39
g/day, P 5 0.015). There were also significant differences
between the nitrogen balances during period 2 versus
period 5 (P 5 0.004) and during period 3 versus period
6 (P 5 0.037).
It may be estimated that between 0.50 and 1.0 g of
nitrogen was lost each day from the body from such
Fig. 2. Serum insulin-like growth factor-1 (IGF-1) profile in six patientsunmeasured outputs as respiration, growth of integu-
receiving rhIGF-1 subcutaneous injections every 12 hours, starting on
mentary structures (epidermis, nails, hair), sweat, flatus, day 16, after the morning blood draw. Note that during the treatment
phase, the serum IGF-1 level was measured 12 hours after the previousand the regeneration of proteins, peptides, and amino
injection and just before the morning rhIGF-1 administration. Theacids lost from blood drawn [21]. If either of these asterisk indicates an overall increase from baseline (P , 0.0001,
amounts of nitrogen are subtracted from the total nitro- ANOVA).
gen output, the average nitrogen balance would still not
differ from zero during each of the three balance periods
in the baseline phase and would be significantly positive significantly greater than the average of the values on
during each of the four balance periods during the treat- days 6, 11, and 16 (P 5 0.031).
ment phase. During treatment with rhIGF-1, possible minor side-
Serum IGF-1 concentrations measured serially in the effects were observed that did not lead to either a reduc-
morning after an overnight fast were rather constant tion of rhIGF-1 dose or withdrawal of treatment. There
during baseline (Fig. 2). The combined average of the was an episode of transient headache and diarrhea in
serum IGF-1 levels on days 6, 11, and 16 was 174 6 103 one patient. Two patients developed sinus tachycardia
mg/L. After inauguration of the 12 hourly injections of within the first week of rhIGF-1 injections, lasting for
rhIGF-1 on day 16, serum IGF-1 concentrations, ob- many minutes with a maximum heart rate of 120; patients
tained before the morning rhIGF-1 injection, rose by were not hypotensive during the tachycardia, and the
approximately 100%. After five days of injections, the electrocardiogram was otherwise normal. Three patients
serum IGF-1 concentrations averaged 347 6 154 mg/L displayed a decrease in blood pressure of about 20 mm
(Fig. 2) and did not change during the 20-day period of Hg; the patients, although asymptomatic, each received
rhIGF-1 injections. The mean serum IGF-1 concentra- an infusion of normal saline and blood pressure returned
to the patient’s normal value.tions on days 26, 31, and 36 (401 6 128 mg/L) were
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DISCUSSION mote a strong anabolic response in malnourished CAPD
patients. With the administration of rhIGF-1, there wasInsulin-like growth factor-1 is a polypeptide of a mo-
a marked reduction in net protein degradation (that is,lecular weight of about 7700 daltons. The actions of
a decrease in total body protein degradation and/or anIGF-1 account for at least most of the anabolic effects
increase in total body protein synthesis), as indicated byof GH. It has only been for about 10 years that rhIGF-1
a decrease in dialysate and urine total nitrogen and inhas been synthesized and has been available in sufficient
SUN in the face of an unchanging dietary protein intake.quantities to conduct studies in humans. IGF-1 decreases
Thus, nitrogen balance became more positive (Table 5).serum glucose; facilitates the intracellular transport of
This anabolic effect of IGF-1 occurred within manyglucose; suppresses lipolysis, protein degradation, and
hours of the first injection of this peptide, as indicatedureagenesis; and enhances protein synthesis, positive ni-
in the three patients in whom daily nitrogen output wastrogen balance, and bone growth [22, 23]. The rhGH-
measured daily (Fig. 1).induced increase in body size is mediated by the actions
It is intriguing that the magnitude of the positive nitro-of IGF-1 [24].
gen balance remained essentially constant for the 20 daysTreatment with rhGH promotes an anabolic response
of rhIGF-1 treatment (Table 5 and Fig. 1). These findingsin patients with chronic renal failure [10, 25, 26]; rhGH
may be different from a number of other types of ana-accelerates growth in children and promotes a positive
bolic interventions, such as nutritional supplements ornitrogen balance in adults with chronic renal failure.
growth hormone treatment. With these other interven-However, several studies of patients who did not have
tions, nitrogen balance may remain positive for extendedrenal disease or who had chronic renal failure indicate
periods of time, but the initial markedly positive effectthat if patients are severely infected, do present a cancer,
tends to become attenuated over a period of one to twoor have low protein and energy intakes, the response to
weeks. The lack of attenuation of the anabolic effectsgrowth hormone may be markedly impaired [12, 27, 28].
of rhIGF-1 in this study may reflect less regulatory con-The lack of an anabolic response is associated with an
trol over the actions of rhIGF-1. For example, the ana-
attenuation in the rise in serum IGF-1 levels, suggesting
bolic effects of growth hormone might be modified by
that it is the reduction in the secretion of IGF-1 in re- up-regulating or down-regulating the growth hormone
sponse to growth hormone that blunts the anabolic effect receptor that stimulates the release of IGF-1. By giving
of growth hormone in some individuals who are septic rhIGF-1, this potential regulatory center can be circum-
or undernourished. Studies in undernourished rats also vented. It should be stressed that the persistence of the
demonstrate that poor nutrition can be associated with strongly positive nitrogen balance for 20 days in this
an impaired anabolic response to growth hormone and study was only observed in six patients. It would be
that this effect is due to a reduction in IGF-1 levels important to confirm this observation for longer periods
[29]. Indeed, there is a relationship between low protein of time in larger numbers of patients before concluding
or energy intake and spontaneously occurring serum that the initial anabolic response to rhIGF-1 is more
IGF-1 concentrations [30]. This relationship is suffi- sustained than other anabolic interventions. In this re-
ciently strong so that some researchers have suggested gard, rhIGF-1 increases renal blood flow and glomerular
that serum IGF-1 may be a marker of nutritional status filtration rate only transiently, for a period of several
or recent nutrient intake in patients [31]. days in individuals with chronic renal insufficiency [36].
We have carried out a series of studies examining the The transitory nature of this effect of rhIGF-1 is thought
nutritional and anabolic effects of IGF-1 in chronic renal to be due to the suppression of growth hormone secre-
failure for several reasons. First, a large proportion of tion and possibly to the resultant decrease in serum IGF
patients with advanced chronic renal failure has protein binding protein 3 (IGFBP-3). It has been suggested that
and/or energy malnutrition [1]. Second, it is often diffi- serum IGFBP-3 may enhance the actions of IGF-1 by
cult to improve the nutritional status of these patients trapping it in plasma [37] and releasing it slowly over
only by dietary counseling or prescription of food supple- time [38]. Whether this effect will impair the long-term
ments. Third, there is resistance to the actions of both anabolic actions of rhIGF-1 is not known.
insulin and IGF-1 in patients with chronic renal failure The dose of peritoneal dialysis may be considered
[32–35]. Thus, such patients might benefit from supple- to be less than optimal, according to the NKF-DOQI
mented IGF-1. Finally, because malnourished patients guidelines [39]. The protocol for this study was designed
with chronic renal failure may eat poorly and be more and implemented before the publication of these guide-
likely to develop intercurrent catabolic illnesses, we were lines. However, the patients did not show evidence for
concerned that an impaired response to rhGH in some metabolic acidosis. The serum bicarbonate averaged
patients might render treatment with this hormone less 23.8 6 1.6 mmol/L (baseline), 25.5 6 2.5 (day 16, start
effective than treatment with rhIGF-1 directly [10, 12]. of rhIGF-1 treatment), and 25.2 6 2.2 (end of rhIGF-1
treatment). Hence, we do not think that any variationThe results of this study show that rhIGF-1 does pro-
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